Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Companies developing microbiome-based therapies have been beset by challenges in the past few years, but hopes remain for some applications and could soon be boosted by the first regulatory approval in the field.
With siRNA-based drugs becoming established as a therapeutic modality, large companies are engaging in the field through deals and acquisitions, and cardiovascular and metabolic diseases are among their targets.
The promise of targeted protein degradation to drug ‘undruggable’ proteins is driving a surge of venture funding and partnerships around this novel therapeutic modality.
Companies applying artificial intelligence tools in small-molecule drug discovery have recently attracted substantial financing and a multitude of large pharma partners.
Oncology-focused partnerships drove record-level licensing deals in 2021 as companies looked to gain access to novel therapeutic targets and platforms.
Infectious disease diagnostics were prominent among mergers and acquisitions in the molecular diagnostics field, while financing flowed to companies developing liquid biopsy technology.